Analysis of The Use of PCSK9 Inhibitors in Clinical Practice

Aim. The analysis of the experience of using PCSK9 inhibitors (alirocumab) in patients with very high cardiovascular risk, according to long observations in real clinical practice.Material and methods. In study evaluated the data for 31 people (23 men and 8 women, the average age of those surveyed was 59.4 +/- 5.8 years) of very high cardiovascular risk with atherogenic dyslipidemia and no achievement of the target lipid levels. Alirokumab was administered in a dose of 150 mg subcutaneously once every 2 weeks in the day hospital of a multidisciplinary clinic. The primary endpoint was reached the target level of low density lipoprotein cholesterol (HS-LDL) level and/or reduce HS-LDL levels by 50% or more. Liver tests, level of creatinine and glycemia were studied to assess safety; side effects studied/Results. The long-term use of alirocumab (on average 7,5 +/- 2,3 months) is well tolerated without adverse reactions and withdrawal syndrome, in the day hospital of a multidisciplinary clinic. 90% of patient have achieved either a target level of HS-LDL less than 1.4 mmol/l or a reduction in HS-LDL by 50% or more. The remaining third of patients achieved both target levels. It can be distinguished a group of patients with a good response to the med-ication, in the first months of administration of alirokumab.Conclusion. The results of conducting an efficiency assessment for use of the alirocumab in a dose of 150 mg subcutaneously within two weeks showed that this therapy has the high efficacy and good tolerability without any adverse reactions, in the day hospital of a multidisciplinary clinic.

Automated summary

The aim of this study was to analyze the experience of using PCSK9 inhibitors (alirocumab) in patients with very high cardiovascular risk based on real clinical practice. The results showed that alirocumab treatment in a day hospital of a multidisciplinary clinic, with a dose of 150 mg subcutaneously every 2 weeks for an average of 7.5 months, was well tolerated without adverse reactions or withdrawal syndrome. 90% of patients achieved the target levels of low density lipoprotein cholesterol (HS-LDL) or a significant reduction in HS-LDL levels.